Lessons from the major studies in COPD: problems and pitfalls in translating research evidence into practice

被引:11
作者
Halpin, David M. G. [1 ]
机构
[1] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England
来源
PRIMARY CARE RESPIRATORY JOURNAL | 2010年 / 19卷 / 02期
关键词
COPD; trials; studies; research; design; methodology; critical analysis; interventions; outcomes; data; OBSTRUCTIVE PULMONARY-DISEASE; FLUTICASONE PROPIONATE/SALMETEROL 250/50; 50; MU-G; SALMETEROL/FLUTICASONE PROPIONATE; COST-EFFECTIVENESS; THERAPEUTIC TRIALS; RANDOMIZED-TRIALS; HEALTH-CARE; EXACERBATIONS; EFFICACY;
D O I
10.4104/pcrj.2010.00015
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Translating the growing evidence base on COPD management into practice can be challenging and understanding the strengths and weakness of published studies is crucial. Studies should conform to the standards of CONSORT statement; they should be sufficiently powered, participants should be randomised, there should be assignment concealment, and the outcome measures and analyses should be decided in advance. The interpretation of the results may be affected by age and severity inclusion criteria for the study and the exclusion of patients with co-morbid illnesses. Whether previous medication is continued or stopped can affect the interpretation of the results. Secondary analyses in sub-groups should be viewed with caution unless pre-specified and accommodated in the trial design and power calculations. Real world observational studies may be confounded by non-randomisation of participants but can sometimes yield valuable insights. The way in which the results are presented can influence their interpretation and their magnitude with respect to minimal important differences as well as statistical significance is important. Research studies help formulate management algorithms but often the questions they address are too specific to allow evidence-based sequencing of therapies. (c) 2010 Primary Care Respiratory Society UK. All rights reserved. DMG Halpin. Prim Care Resp J 2010; 19(2): 170-179 doi:10.4104/pcrj.2010.00015
引用
收藏
页码:170 / 179
页数:10
相关论文
共 62 条
[31]  
Juni P., 2001, SYSTEMATIC REV HLTH, V2nd, P87
[32]   Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease [J].
Kardos, Peter ;
Wencker, Marion ;
Glaab, Thomas ;
Vogelmeier, Claus .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 175 (02) :144-149
[33]   Methods for therapeutic trials in COPD: lessons from the TORCH trial [J].
Keene, O. N. ;
Vestbo, J. ;
Anderson, J. A. ;
Calverley, P. M. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (05) :1018-1023
[34]   Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study [J].
Keene, Oliver N. ;
Jones, Mark R. K. ;
Lane, Peter W. ;
Anderson, Julie .
PHARMACEUTICAL STATISTICS, 2007, 6 (02) :89-97
[35]   ANALYSIS OF CLINICAL-TRIALS BY TREATMENT ACTUALLY RECEIVED - IS IT REALLY AN OPTION [J].
LEE, YJ ;
ELLENBERG, JH ;
HIRTZ, DG ;
NELSON, KB .
STATISTICS IN MEDICINE, 1991, 10 (10) :1595-1605
[36]   INTERPRETATION OF QUALITY-OF-LIFE CHANGES [J].
LYDICK, E ;
EPSTEIN, RS .
QUALITY OF LIFE RESEARCH, 1993, 2 (03) :221-226
[37]  
Mahler Donald A, 2005, COPD, V2, P99
[38]   The NICE cost-effectiveness threshold - What it is and what that means [J].
McCabe, Christopher ;
Claxton, Karl ;
Culyer, Anthony J. .
PHARMACOECONOMICS, 2008, 26 (09) :733-744
[39]  
Miravitlles Marc, 2009, Int J Chron Obstruct Pulmon Dis, V4, P185
[40]   Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? [J].
Moher, D ;
Pham, B ;
Jones, A ;
Cook, DJ ;
Jadad, AR ;
Moher, M ;
Tugwell, P ;
Klassen, TP .
LANCET, 1998, 352 (9128) :609-613